30 results about "Alpha-v beta-3" patented technology

The invention belongs to the technical field of biomedicine production or the fields of protein polypeptide drugs and biomedical engineering, and in particular relates to a polypeptide which has high affinity with an integrin receptor and an application of the polypeptide like cancer diagnosis and treatment. The polypeptide is composed of five amino acids, and the sequence is arginine-tryptophan-arginine-asparagine-methionine (Arg-Trp-Arg-Asn-Met). On the basis of an in-vitro flow cytometry affinity determination experiment, the polypeptide disclosed by the invention has quite strong targeting on high-expression cells of the integrin receptor, and through an in-vitro laser confocal cell uptake experiment, the polypeptide can be targeted to high-expression tumor cells of the integrin receptor alpha-v-beta-3 and can basically avoid targeting on low-expression tumor cells and normal cells of the integrin receptor alpha-v-beta-3. An in-vitro cytotoxicity result shows that the 5-peptide disclosed by the invention is basically free from toxicity on cells, and the 5-peptide has a good application prospect in the diagnosis and the treatment of cancers.

The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (αVβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

The invention discloses a cancer cell-targeting structural molecule and a use thereof. A molecule shown in the formula (I) reacts with a connection molecule containing a carboxyl structure and a maleimide group so that the cancer cell-targeting structural molecule is produced by a dehydration synthesis reaction of an amino group and a carboxyl group. The cancer cell-targeting structural molecule can be bonded with a sulfydryl (-SH)-modified nucleotide molecule, can be directly applied to a human body by blood vessel administration, can be specifically bonded with cancer cells expressing integrin family alpha v beta 3 acceptors or with new vessel endothelial cells in cancer tissue, can effectively penetrate a cell membrane by receptor-mediated endocytosis, and can convey the nucleotide molecule into cytoplasm. In the formula (I), n is in a range of 1-10.